Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding
EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ — Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company’s platform, programs, and data.
Related news for (GYRE)
- Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
- Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
- Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
- Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
- Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications